To track the effectiveness of treatment for invasive breast cancer and to aid in the detection of potential disease recurrence.
To continue booking, you need to select at least 1 test
* Results are available same day by 9 p.m. 99% of the time. On rare occasions, it may take up to 3 business days to receive results.
Cancer antigen 15-3 (CA 15-3) is a protein naturally produced by healthy breast cells. However, individuals with cancerous breast tumors often experience an elevated production of CA 15-3 and its counterpart, cancer antigen 27.29. CA 15-3 does not have a causative role in cancer; instead, it is released into the bloodstream by tumor cells. The CA 15-3 blood test is used to measure the levels of CA 15-3 in the blood.
The CA 15-3 test is occasionally requested to offer a rough estimate of the extent of cancer in the body, often referred to as the tumor burden. It is important to note that CA 15-3 can serve as a marker only if the cancer is actively generating increased quantities of this protein. Consequently, this test may not be applicable for all individuals with breast cancer.
As a general rule, elevated CA 15-3 levels are indicative of more advanced breast cancer and a larger volume of cancerous tissue (tumor burden). CA 15-3 concentrations typically rise as the cancer progresses. In cases of metastatic breast cancer, the highest CA 15-3 levels are often observed when the cancer has disseminated to the bones and/or the liver.
The cancer antigen 15-3 (CA 15-3) test, along with the related CA 27.29 test, is primarily employed to monitor a patient's response to breast cancer treatment and to aid in the surveillance of breast cancer recurrence. These tests are utilized in conjunction with other clinical assessments and breast cancer-related tests like estrogen and progesterone receptor assays, Her2/neu status evaluation, and gene expression tests (e.g., Oncotype DX, MammoPrint) to assess the status of a patient's breast cancer.
In some cases, CA 15-3 may be ordered to provide a rough estimate of the extent of cancer present in the body (tumor burden). It's important to note that CA 15-3 can only serve as a marker if the cancer is actively producing elevated levels of this antigen, so it may not be applicable to all breast cancer patients.
The CA 15-3 and CA 27.29 tests are not suitable for use as general cancer screening tests due to their lack of sensitivity and specificity. Elevated levels of these antigens can also be caused by non-cancerous conditions.
CA 15-3 may be initially ordered along with other tests when advanced breast cancer is diagnosed to assess cancer characteristics and guide treatment decisions. Subsequently, if the CA 15-3 levels are initially elevated, the test may be periodically ordered to monitor the treatment's effectiveness and to surveil for potential recurrence. Typically, CA 15-3 is not requested in cases of early breast cancer detection, before metastasis occurs, as elevated levels are uncommon in the majority of early-stage cancers.
In general, higher CA 15-3 levels are associated with more advanced breast cancer and a larger tumor burden. As breast cancer progresses, CA 15-3 concentrations typically increase, with the highest levels often observed in cases of metastatic breast cancer that has spread to the bones and/or liver.
A rise in CA 15-3 concentrations over time may signal inadequate response to treatment or cancer recurrence.
However, normal CA 15-3 levels do not guarantee the absence of localized or metastatic breast cancer. Elevated CA 15-3 levels may not yet be detectable in early disease stages, or approximately 20% to 25% of individuals with advanced breast cancer may not shed CA 15-3.
Mild to moderate elevations of CA 15-3 are also observed in various non-cancerous conditions, such as lung, pancreas, ovary, prostate, and colon cancers, cirrhosis, hepatitis, benign breast disorders, and in a subset of apparently healthy individuals. In these non-cancerous conditions, CA 15-3 elevations tend to remain relatively stable over time.
CA 15-3 is not recommended for use as a screening tool, as it lacks the necessary specificity and sensitivity to detect early breast cancer. Elevated CA 15-3 levels may be attributed to various non-cancerous conditions, and a normal value does not guarantee the absence of cancer. Typically, CA 15-3 should be employed after breast cancer has already been diagnosed.
Best Prices
Our fully automated private laboratory with cutting edge technology is able to reduce costs while increasing consistency and reproducibility of results.
Faster Service
We have designed our clinics and testing processes to be efficient, reducing wait times and time for results.
More Precise Information
Our test reports provide more precise information on test results, making it easier to monitor any changes in your health over time.
Free Parking
All our clinics provide free and available parking, helping you to save even more money and time.
Customer Support
Our online booking portal and helpful testing center staff help to make diagnostic testing more convenient and compassionate.
IMPLEMENT AFFORDABLE ACTION
Companies and institutions can deploy large-scale diagnostic testing at a fraction of the cost of testing centers with Lilium’s automated laboratory testing platforms and reporting.
STAY AHEAD OF OUTBREAKS
Lilium's pioneering testing system secures workplaces and communities against expensive shutdowns by keeping businesses and organizations ahead of outbreaks.
REDUCE RISKS
Robotic analysis improves accuracy of results by drastically reducing the risk of false negatives and positives.
To make an appointment, please choose from one of our clinics below:
Monday - Saturday
7:00 - 10:00
12:00 - 15:00
We provide FREE parking at our convenient locations
Our downtown Montreal location is located on the mezzanine level of the Alexis Nihon Center with 1 hour free indoor parking. Atwater metro station has a direct inside connection to Alexis Nihon.
If you’re driving to our Laval location, we are right off Autoroute 15 and have plenty of free parking.
If you arrive by public metro, there is a walkway to our lab from Metro Montmorency (a 20 minute walk).
What our customers say about us
ASK US ANYTHING
We're here to help make sense of it all.
Or send us an e-mail